National Amyloidosis Centre Patient Forum
Amyloidosis => Research => Topic started by: patpinchin on July 20, 2016, 07:38:18 pm
-
Hi Miriam,
Encouraging news for cardiac patients. See link below.
If FDA approval is given for the use of NT-proBNP as a biomarker, is it likely to apply to the two current studies for NEOD001 at the NAC?
Is NT-proBNP an approved biomarker for clinical trials in the UK?.
http://finance.yahoo.com/news/amyloidosis-research-consortium-announces-publication-152700555.html
-
Professor Hawkins' answer: It remains to be seen how the FDA and EMA will view cardiac biomarkers as a trial endpoint, this ultimately being tested when the results of a trial are submitted to them.
-
Thank-you Professor Hawkins and Miriam.